Soleno Therapeutics (SLNO) Return on Sales (2015 - 2026)

Soleno Therapeutics (SLNO) posted quarterly Return on Sales of 0.0% for Q1 2026, down 29.83% quarter-over-quarter from 0.0% in Q4 2025.

Soleno Therapeutics (SLNO) Return on Sales (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has reported Return on Sales for 5 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

In Q1 2026, Return on Sales changed N/A year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.01% (changed N/A YoY), while the FY2025 annual figure was 0.0%, changed N/A from the prior year.
Return on Sales eased to 0.0% in Q1 2026 per SLNO's latest filing, from 0.0% in the prior quarter.
Across five years, Return on Sales topped out at 0.0% in Q4 2025 and bottomed at 0.05% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Soleno Therapeutics	2.74 Bn	2.49 Bn	93.41 Mn	0.00%

Download Data